ZNTL - Zentalis Pharmaceuticals, Inc.
4.05
-0.200 -4.938%
Share volume: 1,180,353
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$4.25
-0.20
-0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-09-2024 | 11-12-2024 | 03-26-2025 | 05-14-2025 | 11-10-2025 | 03-26-2026 | |
| Total revenue | 40.560 M | 0.000 | 0.000 | 26.865 M | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 40.560 M | 0.000 | 0.000 | 26.865 M | 0.000 | 0.000 | 0.000 | |
| -100.00% | nan% | inf% | -100.00% | nan% | nan% | |||
| Operating expenses | 65.325 M | 65.148 M | 51.432 M | 72.978 M | 37.827 M | 33.734 M | 37.393 M | |
| Selling general and admin | 15.740 M | 16.762 M | 14.608 M | 40.005 M | 10.580 M | 10.784 M | 7.905 M | |
| Research and development | 49.585 M | 48.386 M | 36.824 M | 32.973 M | 27.247 M | 22.950 M | 29.488 M | |
| Total expenses | 65.325 M | 65.148 M | 51.432 M | 76.714 M | 45.623 M | 33.734 M | 37.393 M | |
| -0.27% | -21.05% | 49.16% | -40.53% | -26.06% | 10.85% | |||
| Operating income | -24.765 M | -65.148 M | -51.432 M | -49.849 M | -45.623 M | -33.734 M | -37.393 M | |
| Ebit | 10.183 M | -88.011 M | -40.185 M | -47.677 M | -48.279 M | -26.691 M | -34.774 M | |
| Pretax income | 10.183 M | -88.011 M | -40.185 M | -47.677 M | -48.279 M | -26.691 M | -34.774 M | |
| -964.29% | -54.34% | 18.64% | 1.26% | -44.72% | 30.28% | |||
| Income tax | 143.000 K | 266.000 K | -27.000 K | -205.000 K | 0.000 | 0.000 | 442.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 10.040 M | -88.277 M | -40.158 M | -47.472 M | -48.279 M | -26.691 M | -35.216 M | |
| -979.25% | 54.51% | -18.21% | -1.70% | 44.72% | -31.94% |